Skip to main content

Epilepsy, Tonic-Clonic

Neurology
7
Pipeline Programs
6
Companies
7
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
5
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

On Market (4)

Approved therapies currently available

GSK
LAMICTALApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral1994
112M Part D
GSK
LAMICTAL XRApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral2009
53M Part D
GSK
LAMICTAL ODTApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral2009
3M Part D
GSK
LAMICTAL CDApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral1998

Competitive Landscape

6 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
1
1
lamotriginePhase 4
lamotriginePhase 3
Topiramate coated tabletPhase 1
GSK
GSKLONDON, United Kingdom
2 programs
1
Topiramate coated tabletPHASE_11 trial
lamotriginePHASE_41 trial
Active Trials
NCT01439438Completed26Est. Sep 2011
NCT00043901Completed141Est. Mar 2005
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
LEVETIRACETAMPHASE_31 trial
LevetiracetamPHASE_31 trial
Active Trials
NCT00150787Completed250Est. Nov 2005
NCT00150813Completed66Est. May 2007
LivaNova
LivaNovaUK - London
1 program
Accelerometer Live-Streaming ToolN/A1 trial
Active Trials
NCT04282681Withdrawn0Est. Feb 2022
Precision BioSciences
1 program
vormatroginePHASE_3
Praxis Precision Medicines
1 program
vormatroginePHASE_32 trials
Active Trials
NCT07505004Recruiting300Est. May 2027
NCT07287163Enrolling By Invitation700Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
GSKlamotrigine
Praxis Precision Medicinesvormatrogine
Praxis Precision Medicinesvormatrogine
UCB PharmaLevetiracetam
UCB PharmaLEVETIRACETAM
GSKTopiramate coated tablet
LivaNovaAccelerometer Live-Streaming Tool

Clinical Trials (7)

Total enrollment: 1,483 patients across 7 trials

NCT00043901GSKlamotrigine

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

Start: Dec 2000Est. completion: Mar 2005141 patients
Phase 4Completed

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Start: Jan 2026Est. completion: May 2027300 patients
Phase 3Recruiting

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Start: Oct 2025Est. completion: Dec 2028700 patients
Phase 3Enrolling By Invitation

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Start: Aug 2005Est. completion: May 200766 patients
Phase 3Completed

Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.

Start: Jul 2003Est. completion: Nov 2005250 patients
Phase 3Completed
NCT01439438GSKTopiramate coated tablet

Topiramate Bioequivalence Study Brazil - Fast

Start: Jul 2011Est. completion: Sep 201126 patients
Phase 1Completed
NCT04282681LivaNovaAccelerometer Live-Streaming Tool

XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)

Start: Mar 2020Est. completion: Feb 20220
N/AWithdrawn

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,483 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.